Galectin Therapeutics Inc. (GALT) News
Filter GALT News Items
GALT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest GALT News From Around the Web
Below are the latest news stories about GALECTIN THERAPEUTICS INC that investors may wish to consider to help them evaluate GALT as an investment opportunity.
Galectin Therapeutics Inc (GALT) Reports Increased Net Loss in Q3 2023Company Faces Higher R&D Expenses Amid Progress in Clinical Programs |
UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateNORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President |
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateNORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President |
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLDPharmacokinetics and safety of belapectin in patients with hepatic insufficiencyLack of impact of belapectin on cardiac repolarization (QT interval)Very High Elevation of Gamma-Glutamyl Transpeptidase (GGT) as a new marker of disease progression in patient with portal hypertension and liver cirrhosisClinical significance and interpretation of serum galectin-3 levels in patients with advanced liver diseaseImpact of obesity and muscle wasting to evaluate renal function in patients with portal hype |
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023NORCROSS, Ga., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 7th Annual NASH Investor Conference being held virtually on October 24, 2023. Dr. Pol F. Boudes, Galectin Therapeutics’ Chief Medical Officer, will deliver a corporate presentation on Tuesday, October 24, 2023 at 11:30 AM ET. A live webcast of the discussion will be |
Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of DirectorsNORCROSS, Ga., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Benjamin S. Carson, Sr. has been nominated to serve on the company’s board of directors. Dr. Carson has served as a senior advisor to Galectin Therapeutics since 2021. In this role, he has increased awareness of Galectin’s ongoing Phase 2b/3 NAVIGATE clinical trial in cirrhosis caused by nonalcoholic steatohepati |
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver CirrhosisNORCROSS, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its fourth data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, Phase 2b/3 study of belapectin in patients with portal hypertension caused by non-alcoholic steatohepatitis (NASH) liver cirrhosis. NAVIGATE is the first study of its kind and is a global effort that randomize |
Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023NORCROSS, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced it will participate in the 20th edition of the Discovery on Target meeting, the industry’s preeminent event on Novel Drug Targets and Technologies. The Company will present an update on its belapectin liver cirrhosis program during the Fibrosis and Inflammation session. The presentation, titled “Targeting Activated Macrophages |
Galectin Therapeutics Inc. (NASDAQ:GALT) surges 16%; individual investors who own 59% shares profited along with insidersKey Insights Significant control over Galectin Therapeutics by individual investors implies that the general public has... |
Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023NORCROSS, Ga., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11-13, 2022. The Wainwright Conference – which takes place at the Lotte New York Palace Hotel in New York City, New York – brings together thought leaders and practitioners from numerous fields to par |